HBeAg-negative/ HBeAg-positive / anti-HBeAg/ HBeAg Seroconversion

Half of HBeAg Negative Chronic Hepatitis B Patients Maintain Response up to 5 Years after Stopping Long-term Adefovir (Hepsera)
5/05/09

Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Positive Patients With Chronic Hepatitis B (Study 103)
3/27/09

Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Participating in Studies 102 and 103
3/27/09

Liver Cirrhosis Is Common in HBeAg Negative Chronic Hepatitis B Patients, especially Those with High ALT and HBV DNA Levels
1/23/2009

Tenofovir (Viread) Produces Continued HBV Suppression through 96 Weeks in HBeAg Positive and Negative Patients: Studies 102 and 103
11/05/2008

Long-term Entecavir (Baraclude) Reverses Liver Fibrosis in HBeAg Positive and HBeAg Negative Chronic Hepatitis B Patients
11/05/2008

Long-term Efficacy and Safety of Adefovir (Hepsera) for the Treatment of Chronic Hepatitis B in HBeAg Positive Patients
10/03/08

Sustained HBeAg and HBsAg Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon
9/25/08

High Pre-treatment ALT Levels May Predict Earlier HBeAg Seroconversion in Chronic Hepatitis B Patients Treated with Lamivudine (Epivir-HBV)
9/16/08

Entecavir (Baraclude) Produces Greater Decrease in HBV DNA than Adefovir (Hepsera) in Treatment-naive HBeAg+ Patients: 96 Week Data from EARLY Study
5/06/08

HBeAg and HBV DNA Predict Outcomes of Pegylated Interferon Therapy for Chronic Hepatitis B
2/19/08

Disease Progression in Patients with HBeAg-negative Chronic Hepatitis B
1/29/08